Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons.
budgetary impact
computer simulation model
cost-effectiveness
hepatitis C
prisons
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
17 03 2020
17 03 2020
Historique:
received:
05
12
2018
accepted:
14
05
2019
pubmed:
17
5
2019
medline:
7
1
2021
entrez:
17
5
2019
Statut:
ppublish
Résumé
Hepatitis C virus (HCV) testing and treatment uptake in prisons remains low. We aimed to estimate clinical outcomes, cost-effectiveness (CE), and budgetary impact (BI) of HCV testing and treatment in United States (US) prisons or linkage to care at release. We used individual-based simulation modeling with healthcare and Department of Corrections (DOC) perspectives for CE and BI analyses, respectively. We simulated a US prison cohort at entry using published data and Washington State DOC individual-level data. We considered permutations of testing (risk factor based, routine at entry or at release, no testing), treatment (if liver fibrosis stage ≥F3, for all HCV infected or no treatment), and linkage to care (at release or no linkage). Outcomes included quality-adjusted life-years (QALY); cases identified, treated, and cured; cirrhosis cases avoided; incremental cost-effectiveness ratios; DOC costs (2016 US dollars); and BI (healthcare cost/prison entrant) to generalize to other states. Compared to "no testing, no treatment, and no linkage to care," the "test all, treat all, and linkage to care at release" model increased the lifetime sustained virologic response by 23%, reduced cirrhosis cases by 54% at a DOC annual additional cost of $1440 per prison entrant, and would be cost-effective. At current drug prices, targeted testing and liver fibrosis-based treatment provided worse outcomes at higher cost or worse outcomes at higher cost per QALY gained. In sensitivity analysis, fibrosis-based treatment restrictions were cost-effective at previous higher drug costs. Although costly, widespread testing and treatment in prisons is considered to be of good value at current drug prices.
Sections du résumé
BACKGROUND
Hepatitis C virus (HCV) testing and treatment uptake in prisons remains low. We aimed to estimate clinical outcomes, cost-effectiveness (CE), and budgetary impact (BI) of HCV testing and treatment in United States (US) prisons or linkage to care at release.
METHODS
We used individual-based simulation modeling with healthcare and Department of Corrections (DOC) perspectives for CE and BI analyses, respectively. We simulated a US prison cohort at entry using published data and Washington State DOC individual-level data. We considered permutations of testing (risk factor based, routine at entry or at release, no testing), treatment (if liver fibrosis stage ≥F3, for all HCV infected or no treatment), and linkage to care (at release or no linkage). Outcomes included quality-adjusted life-years (QALY); cases identified, treated, and cured; cirrhosis cases avoided; incremental cost-effectiveness ratios; DOC costs (2016 US dollars); and BI (healthcare cost/prison entrant) to generalize to other states.
RESULTS
Compared to "no testing, no treatment, and no linkage to care," the "test all, treat all, and linkage to care at release" model increased the lifetime sustained virologic response by 23%, reduced cirrhosis cases by 54% at a DOC annual additional cost of $1440 per prison entrant, and would be cost-effective. At current drug prices, targeted testing and liver fibrosis-based treatment provided worse outcomes at higher cost or worse outcomes at higher cost per QALY gained. In sensitivity analysis, fibrosis-based treatment restrictions were cost-effective at previous higher drug costs.
CONCLUSIONS
Although costly, widespread testing and treatment in prisons is considered to be of good value at current drug prices.
Identifiants
pubmed: 31095676
pii: 5490662
doi: 10.1093/cid/ciz383
pmc: PMC7318776
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1388-1396Subventions
Organisme : NIDA NIH HHS
ID : K23 DA044085
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI042853
Pays : United States
Organisme : NIDA NIH HHS
ID : P30 DA040500
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA046527
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Clin Infect Dis. 2018 Jan 18;66(3):376-384
pubmed: 29020317
JAMA. 2018 Nov 20;320(19):1977-1978
pubmed: 30383176
N Engl J Med. 2015 Dec 31;373(27):2599-607
pubmed: 26571066
Hepatology. 2011 Mar;53(3):726-36
pubmed: 21319189
Drug Alcohol Depend. 2015 Jan 1;146:45-51
pubmed: 25468816
Bull World Health Organ. 2013 Feb 1;91(2):102-23
pubmed: 23554523
Hepatology. 2015 Mar;61(3):783-9
pubmed: 25348499
Ann Intern Med. 2016 Jan 19;164(2):84-92
pubmed: 26595252
Ann Intern Med. 2015 May 5;162(9):619-29
pubmed: 25820703
Med Decis Making. 2008 Jul-Aug;28(4):582-92
pubmed: 18424560
J Viral Hepat. 2006 Jan;13(1):34-41
pubmed: 16364080
Soc Sci Med. 2012 Jul;75(1):240-7
pubmed: 22516762
J Viral Hepat. 2016 Jun;23(6):447-54
pubmed: 26840452
Am J Epidemiol. 2003 Oct 1;158(7):695-704
pubmed: 14507606
Ann Intern Med. 2016 Sep 6;165(5):345-55
pubmed: 27322622
Ann Intern Med. 2014 Oct 21;161(8):546-53
pubmed: 25329202
PLoS One. 2014 May 19;9(5):e97317
pubmed: 24842841
Top Antivir Med. 2013 Feb-Mar;21(1):27-35
pubmed: 23596276
Addiction. 2015 Jun;110(6):996-1005
pubmed: 25644938
Public Health Rep. 2014 Mar-Apr;129(2):187-95
pubmed: 24587554
Int J Drug Policy. 2015 Oct;26(10):911-21
pubmed: 26298331
J Viral Hepat. 2013 Nov;20(11):745-60
pubmed: 24168254
Hepatology. 2008 Nov;48(5):1387-95
pubmed: 18924228
Health Aff (Millwood). 2016 Oct 1;35(10):1893-1901
pubmed: 27702964
Med Decis Making. 2006 Jul-Aug;26(4):410-20
pubmed: 16855129
J Clin Gastroenterol. 2011 Feb;45(2):e17-24
pubmed: 20628308
Am J Public Health. 2015 Jul;105(7):e5-16
pubmed: 25973818
J Infect Dis. 2015 Nov 1;212(9):1407-19
pubmed: 25883387
Am J Gastroenterol. 2009 May;104(5):1147-58
pubmed: 19352340
AIDS. 2014 Jan 28;28(3):365-76
pubmed: 24670522